Novo Nordisk could spend up to $2bn (€1.8bn) on two facilities to support its diabetes portfolio, including an oral long-acting GLP-1 analogue set to enter Phase III trials.
US researchers say 3-D printed microscopic fish robots will allow intelligent drug delivery.
A UK man has been sentenced to 16 months in prison for smuggling illegal erectile dysfunction drugs following an MHRA investigation.
Novo Nordisk has confirmed it will build an API plant in the US, telling this publication a desire to have manufacturing capacity in the key market drove the decision.
Product problems for Allergan and Danish Leo Pharma, plus the Japanese regulator reviews a Bristol-Myers Squibb mAb.
The Japanese Government says consolidation of the country’s generics sector is needed to secure supplies.
Pharma firms developing inhalable drugs often fail to test that their formulations are compatible with their intended delivery devices early enough according to Intertek.